Latest news with #PerkinElmer
Yahoo
3 days ago
- Business
- Yahoo
Agilent Technologies, Merck KGaA, and PerkinElmer Lead with Advanced Analytical and Life Science Solutions
The Environmental Testing Companies Quadrant by MarketsandMarkets 360 offers an in-depth analysis of the global environmental testing market, highlighting over 120 evaluated companies with the Top 15 recognized as quadrant leaders. The market is propelled by stringent regulations, industrialization, and pollution impact awareness, driving demand for advanced testing solutions. Key insights include government-imposed standards for air, water, and soil quality compliance, climate change initiatives, and the rise of IoT and AI technologies. Notable players like Agilent Technologies, Merck KGaA, and PerkinElmer are enhancing their market presence through innovations and strategic partnerships. Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Environmental Testing Products Company Evaluation Report" has been added to Environmental Testing Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Environmental Testing. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. 360 Quadrants evaluated over 120 companies, of which the Top 15 Environmental Testing Companies were categorized and recognized as the quadrant market is experiencing strong growth, driven by stringent environmental regulations, rapid industrialization, and heightened awareness of pollution's health impacts. Governments across the globe are enforcing strict compliance standards for air, water, and soil quality, prompting industries to adopt advanced environmental testing solutions. Additionally, climate change initiatives and sustainability targets are accelerating the demand for real-time monitoring systems, IoT-enabled sensors, and AI-powered analytics. Rising incidents of soil and water contamination, along with the expansion of renewable energy projects and smart city developments, are further boosting market demand. As both industries and governments place greater emphasis on environmental protection, the need for accurate, efficient, and technology-driven testing solutions continues to top criteria for product footprint evaluation included the tested material(microbial contamination, organic compounds, heavy metals, residues, and solids). By sample (wastewater or effluent, soil, air, and others, such as fuel and chemicals). By technology (rapid testing, conventional methods). By end user (agriculture & irrigation sector, government institutes, research and academic institutions, healthcare, industries, and forestry & geology).Key Players:Some of the prominent players are Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Waters Corporation (US), Merck KGaA (Germany), and others. These players are increasingly focusing on product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, sales contracts, and alliances to strengthen their presence in the global 3 Companies Agilent Technologies, Technologies is a global leader in the life sciences, diagnostics, and applied chemical markets, offering a comprehensive suite of solutions that includes instruments, software, services, and consumables designed to support the entire laboratory workflow. The company operates across three core business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. Within the Life Sciences and Applied Markets segment, Agilent provides advanced instrumentation such as liquid chromatography/mass spectrometry (LC/MS), gas chromatography/mass spectrometry (GC/MS), and inductively coupled plasma mass spectrometry (ICP-MS) - key technologies used in environmental testing and related KGaAMerck KGaA is a global science and technology company involved in the development, production, marketing, and distribution of pharmaceuticals, biopharmaceuticals, specialty chemicals, high-performance materials, and life science tools. In 2015, Merck KGaA significantly expanded its footprint in the life sciences sector through the acquisition of Sigma-Aldrich (US).The company is structured into three main business segments: Healthcare (including Merck Serono, Consumer Health, Allergopharma, and Biosimilars), Performance Materials, and Life Science (operated under the Merck Millipore brand). Within the Life Science segment, Merck Millipore offers cutting-edge solutions for PFAS trace analysis, supporting environmental testing and regulatory compliance. Merck KGaA maintains a strong global presence with operations across Europe, North America, Latin America, Asia Pacific, and Africa. Its major subsidiaries include Merck Serono GmbH, Merck Consumer Health Holding GmbH, Merck Selbstmedikation, Merck Chemicals GmbH, and Merck Schuchardt OHG, all headquartered in is a prominent provider of technologies, services, and solutions catering to the diagnostics, life sciences, environmental, industrial, and laboratory sectors. In March 2023, its Life Science and Diagnostics division was spun off into a separate entity named Revvity, allowing the company to streamline its focus. PerkinElmer operates through two main segments: Discovery & Analytical Solutions and Diagnostics. Within the Discovery & Analytical Solutions segment - specifically under the Applied Markets division - PerkinElmer offers a broad range of mass spectrometry instruments used in environmental analysis and other scientific applications. Its customer base includes pharmaceutical and biotech companies, as well as academic and research Topics Covered: 1 Introduction1.1 Market Definition1.2 Inclusions & Exclusions1.3 Market Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Rising Technological Innovations in Environmental Testing3.2.1.2 Growing Public Awareness Related to Health Impact of Pollution3.2.1.3 Development of Portable and Real-Time Environmental Monitoring Technologies3.2.1.4 Increased Participation of Government and Regulatory Bodies in Monitoring Environmental Conditions3.2.2 Restraints3.2.2.1 Expensive Consumables and High Maintenance Cost of Mass Spectrometry Instruments3.2.2.2 Technological Limitations in Mass Spectrometry3.2.3 Opportunities3.2.3.1 Increasing Government Focus on Contaminant Detection3.2.3.2 Increased Utilization of Ai-Driven Analytical Tools to Detect Air and Soil Pollution3.2.3.3 Advancements in Environmental Testing Infrastructure3.2.4 Challenges3.2.4.1 Increased Operational Complexity of Mass Spectrometry Products3.2.4.2 Lack of Skilled Professionals3.3 Trends/Disruptions Impacting Customers' Businesses3.4 Value Chain Analysis3.4.1 Research & Product Development3.4.2 Raw Material Procurement and Manufacturing3.4.3 Distribution and Marketing & Sales3.4.4 Post-Sales Services3.5 Supply Chain Analysis3.5.1 Prominent Companies3.5.2 Small and Medium-Sized Enterprises3.5.3 Distributors3.5.4 End-users3.6 Ecosystem Analysis3.6.1 Role in Ecosystem3.7 Technology Analysis3.7.1 Key Technologies3.7.1.1 Mass Spectrometry (Ms)3.7.1.2 Liquid Chromatography-Mass Spectrometry (Lc-Ms)3.7.1.3 Gas Chromatography-Mass Spectrometry (Gc-Ms)3.7.2 Complementary Technologies3.7.2.1 Laboratory Process Automation3.7.2.2 Cloud Computing3.7.3 Adjacent Technologies3.7.3.1 Environmental Sensors3.8 Patent Analysis3.9 Key Conferences & Events, 2025-20263.10 Porter's Five Force Analysis3.10.1 Bargaining Power of Suppliers3.10.2 Bargaining Power of Buyers3.10.3 Threat of New Entrants3.10.4 Threat of Substitutes3.10.5 Intensity of Competitive Rivalry3.11 Unmet Needs3.12 Impact of Gen Ai/Ai on Environmental Testing Products Market3.12.1 Market Potential of Environmental Testing Products3.12.2 Ai Use Cases3.12.3 Key Companies Implementing Ai3.12.4 Future of Ai in Environmental Testing Products Ecosystem4 Competitive Landscape4.1 Overview4.2 Key Player Strategies/Right to Win4.2.1 Overview of Strategies Adopted by Players in Environmental Testing Products Market4.3 Revenue Analysis, 2019-20234.4 Market Share Analysis, 20234.5 Company Valuation and Financial Metrics4.5.1 Company Valuation4.5.2 Financial Metrics4.6 Brand/Product Comparison4.7 Company Evaluation Matrix: Key Players, 20244.7.1 Stars4.7.2 Emerging Leaders4.7.3 Pervasive Players4.7.4 Participants4.7.5 Company Footprint: Key Players, 20244.7.5.1 Company Footprint4.7.5.2 Region Footprint4.7.5.3 Type Footprint4.7.5.4 Technology Footprint4.7.5.5 Application Footprint4.7.5.6 End-User Footprint4.8 Company Evaluation Matrix: Startups/Smes, 20244.8.1 Progressive Companies4.8.2 Responsive Companies4.8.3 Dynamic Companies4.8.4 Starting Blocks4.8.5 Competitive Benchmarking: Startups/Smes, 20244.8.5.1 Detailed List of Key Startups/Smes4.8.5.2 Competitive Benchmarking of Key Startups/Smes4.9 Competitive Scenario4.9.1 Product Launches4.9.2 Deals4.9.3 Expansions5 Company Profiles Agilent Technologies, Inc. Thermo Fisher Scientific Inc. Waters Corporation Danaher Bruker Shimadzu Corporation Perkinelmer Jeol Ltd. Hitachi High-Tech Corporation Teledyne Technologies Incorporated Ametek, Inc. Jasco Corporation Merck KGaA Leco Corporation Analytik Jena GmbH+Co. Kg Hiden Analytical Rigaku Holdings Corporation Youngin Chromass Scion Instruments Restek Corporation Kore Technology Process Insights, Inc. Masstech Advion, Inc. Skyray Instruments Usa, Inc. Microsaic For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
28-07-2025
- Business
- Yahoo
Revvity (NYSE:RVTY) Surprises With Q2 Sales
Life sciences company Revvity (NYSE:RVTY) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 4.1% year on year to $720.3 million. The company expects the full year's revenue to be around $2.86 billion, close to analysts' estimates. Its non-GAAP profit of $1.18 per share was 3.4% above analysts' consensus estimates. Is now the time to buy Revvity? Find out in our full research report. Revvity (RVTY) Q2 CY2025 Highlights: Revenue: $720.3 million vs analyst estimates of $712.3 million (4.1% year-on-year growth, 1.1% beat) Adjusted EPS: $1.18 vs analyst estimates of $1.14 (3.4% beat) Adjusted EBITDA: $203.7 million vs analyst estimates of $205.5 million (28.3% margin, 0.9% miss) The company slightly lifted its revenue guidance for the full year to $2.86 billion at the midpoint from $2.85 billion Management lowered its full-year Adjusted EPS guidance to $4.90 at the midpoint, a 1% decrease Operating Margin: 12.6%, in line with the same quarter last year Free Cash Flow Margin: 16%, down from 19.7% in the same quarter last year Organic Revenue rose 3% year on year (-1% in the same quarter last year) Market Capitalization: $12.22 billion 'The power of Revvity's transformation and consistent execution were evident in our second-quarter performance, enabling us to exceed expectations despite the evolving market environment,' said Prahlad Singh, president and chief executive officer of Revvity. Company Overview Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Revvity's demand was weak over the last five years as its sales fell at a 1.2% annual rate. This was below our standards and is a sign of poor business quality. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Revvity's revenue over the last two years was flat, sugggesting its demand was weak but stabilized after its initial drop. We can better understand the company's sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Revvity's organic revenue was flat. Because this number aligns with its normal revenue growth, we can see the company's core operations (not acquisitions and divestitures) drove most of its results. This quarter, Revvity reported modest year-on-year revenue growth of 4.1% but beat Wall Street's estimates by 1.1%. Looking ahead, sell-side analysts expect revenue to grow 4.8% over the next 12 months. While this projection implies its newer products and services will fuel better top-line performance, it is still below the sector average. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Revvity has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 21.6%. Looking at the trend in its profitability, Revvity's operating margin decreased by 18.5 percentage points over the last five years. Even though its historical margin was healthy, shareholders will want to see Revvity become more profitable in the future. In Q2, Revvity generated an operating margin profit margin of 12.6%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Revvity's EPS grew at an unimpressive 1% compounded annual growth rate over the last five years. This performance was better than its 1.2% annualized revenue declines, but we take it with a grain of salt because its operating margin didn't improve and it didn't repurchase its shares, meaning the delta came from reduced interest expenses or taxes. In Q2, Revvity reported EPS at $1.18, down from $1.22 in the same quarter last year. Despite falling year on year, this print beat analysts' estimates by 3.4%. Over the next 12 months, Wall Street expects Revvity's full-year EPS of $4.89 to grow 8.2%. Key Takeaways from Revvity's Q2 Results It was good to see Revvity narrowly top analysts' revenue expectations this quarter. We were also happy its EPS outperformed Wall Street's estimates. On the other hand, its full-year EPS guidance slightly missed. Zooming out, we think this was a mixed quarter. The stock remained flat at $103.70 immediately after reporting. Big picture, is Revvity a buy here and now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
PFAS Testing Market Forecast Report 2024-2025 & 2030: Growth Opportunities Presented by Major Markets and Growing Financial Support for Treatment Projects and Programs
Despite technological advancements in mass spectrometry and chromatography, the market faces challenges due to the lack of standard testing methods for PFAS in non-drinking water matrices. The LC-MS-MS segment dominated in 2023, while EPA protocols are highly sought after for their accuracy. North America, with its stringent regulations, leads the market, driven by increased awareness of PFAS health impacts. Key companies include Agilent Technologies, PerkinElmer, and Thermo Fisher Scientific. PFAS Testing Market Dublin, April 17, 2025 (GLOBE NEWSWIRE) -- "PFAS Testing Market by Product Type (Instrument (LC-MS, GC, NMR), Consumables (Coloumns, Solvents, Reagents), Software), Technique (LC- MS-MS, CIC), Method (EPA, ISO, DIN, ASTM), Application (Water, F&B, Soil, Air, Blood/Serum) - Global Forecast to 2030" has been added to offering. The global PFAS testing market is projected to expand from USD 429.2 million in 2024 to USD 969.5 million by 2030, registering a CAGR of 14.5% The report provides stakeholders with an accurate estimation of the PFAS testing market and its segments. It helps market entrants understand the competitive landscape and craft effective market strategies. Detailed analysis of market drivers, constraints, opportunities, and challenges is provided. Advanced mass spectrometry and chromatography technologies are significantly improving contaminant detection accuracy and efficiency. However, the market faces challenges due to the lack of standardized test methods for PFAS analysis in matrices other than drinking water, impacting regulatory and data accuracy issues across industries like agriculture, packaging, and wastewater management. The technique segment to hold the largest share of the market in 2023. PFAS testing is categorized into techniques such as LC-MS-MS, GC/MS, mass spectrometry, NMR spectroscopy, and others. The LC-MS-MS segment dominated the market in 2023, owing to the integration of liquid chromatography with advanced tandem mass spectrometers. This integration enables high-throughput analysis with minimal sample preparation, enhancing accuracy and sensitivity. Such advancements have broadened the application across industries such as pharmaceuticals, environmental monitoring, and food safety analysis. The EPA segment to hold the largest share of the market in 2023. The market segments for PFAS testing include EPA, DIN, ISO, ASTM, among others. The EPA segment is set to lead due to rising awareness about the health hazards of PFAS contaminants, linked to diseases like cancer and liver dysfunction. Global regulatory bodies are tightening PFAS limits, driving the demand for precise testing protocols. EPA-validated methodologies like EPA 537, 533, and 8327 are preferred due to their sensitivity and specificity in analyzing multiple PFAS compounds. This focus on environmental protection and public health continues to drive EPA-based testing solutions. The market in the North America region is expected to hold a significant market share for PFAS testing in 2024. North America led the PFAS testing market owing to stringent government regulations, robust enforcement strategies, and heightened consumer awareness about PFAS hazards. Increased investments in environmental study and remediation are boosting new PFAS testing technology adoption. Regulatory frameworks by the U.S. EPA and Environment Canada emphasize stringent PFAS monitoring, contributing to market dominance. Future investments in lab facilities and advanced methods will likely sustain North America's leadership in the PFAS testing market. Key Companies Profiled in the Report: Leading market players include Merck KGaA (Germany), Agilent Technologies (US), LGC Limited (UK), Waters Corporation (US), Biotage (Sweden), AccuStandard, Inc. (US), PerkinElmer, Inc. (US), Thermo Fisher Scientific, Inc. (US), Phenomenex (US), MACHEREY-NAGEL GmbH & Co. KG (Germany), and Shimadzu Corporation (Japan). Key Benefits of Buying the Report Analysis of key drivers (regulatory reforms, public awareness, investment climate, financial support for projects). Product Development/Innovation: Insights on technologies, R&D activities, product launches in PFAS testing. Market Development: Comprehensive information about lucrative markets and regional analysis. Market Diversification: Information on new products, geographies, and investments. Competitive Assessment: Analysis of market shares, strategies, and offerings of leading players, including recent developments and financial metrics in the PFAS testing market. Key Attributes: Report Attribute Details No. of Pages 332 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $429.2 Million Forecasted Market Value (USD) by 2030 $969.5 Million Compound Annual Growth Rate 14.5% Regions Covered Global Market Dynamics Drivers Regulatory Reforms Addressing Environmental Pollution Growing Concerns Over PFAS Contamination in Water Favorable Investment Climate Driving Improvements in Environmental Capabilities Increasing Financial Support for Wastewater Treatment Projects and Programs Challenges Lack of Standardized Testing Methods Across Regions Limited Availability of Skilled Labor Opportunities Growth Opportunities Presented by Major Markets Growing Financial Support for Treatment Projects and Programs Higher Public Awareness Regarding Population Levels Company Profiles Agilent Technologies, Inc. Danaher Corporation Waters Corporation. Thermo Fisher Scientific Inc. Shimadzu Corporation Merck KGaA Perkinelmer Inc. Lgc Limited Biotage Macherey-Nagel GmbH & Co. KG Accustandard Wellington Laboratories Inc. Cambridge Isotope Laboratories, Inc. Chiron As Metrohm Inula GmbH Restek Corporation Microsaic Evonik Lctech Absolute Standards Inc. Cytiva Avantor, Inc. Greyhound Chromatography and Allied Chemicals Ltd. Lanxess The Chemours Company For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment PFAS Testing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Reuters
31-01-2025
- Business
- Reuters
Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending
Jan 31 (Reuters) - Medical equipment maker Revvity (RVTY.N), opens new tab forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research. The company has faced challenges from reduced spending from biotech clients and smaller drug developers amid higher-for-longer interest rates. The diagnostic products and scientific tools manufacturer forecast 2025 adjusted profit to be in the range of $4.90 to $5.00 per share, the mid-point of which is below analysts' estimates of $4.99, as per data compiled by LSEG. Advertisement · Scroll to continue Report this ad Revvity expects 2025 revenue to be in the range of $2.80 billion to $2.85 billion, compared with estimates of $2.87 billion. The company, however, beat fourth-quarter profit and revenue estimates, on the back of strong sales in its life sciences and diagnostics units. On an adjusted basis, Revvity earned a profit of $1.42 per share, topping analysts' estimates of $1.37. The Massachusetts-based company reported fourth-quarter revenue of $729.4 million, compared with estimates of $727.9 million. The company's life sciences unit, which provides reagents and instruments for drug discovery, brought in revenue of $336.3 million during the quarter, compared with estimates of $327.9 million. Sales in its diagnostic unit, which provides testing tools for processes such as genetic screening, rose 4% to $393.2 million. Formerly known as PerkinElmer, the company divested three of its businesses in 2022 to focus on life sciences and diagnostics units. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
